Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Maves vs Ryze Rx

Maves
Graded #91

Higher grade

vs+13.399999999999991
Ryze Rx
Graded #376

Lower grade

The verdict

Maves takes it — 71.6/100 to 58.2/100.

Maves grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMaves +39
83
44
Dose & formulationMaves +1
65
64
Clinical oversightMaves +1
76
75
Labs & monitoringEven
52
52
FulfillmentMaves +18
87
69
Contract termsMaves +14
55
41
Maves · left barRyze Rx · right bar

The numbers

MetricMavesRyze Rx
WeighScore71.6/10058.2/100
GradeCC
Scorecard rank#91#376
Semaglutide$99/mo (starting dose, first-month rate, compounded)$199/mo (starting dose, 3 month plan, compounded)
TirzepatideNot disclosed$199/mo (starting dose, 3 month plan, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Maves

Graded #91 · C

Strengths

  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
  • All 50 states covered, stated explicitly
  • Both brand (Maves) and parent (Homera Health) disclosed for accountability

Where it loses points

  • 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
  • Tirzepatide pricing not stated on the homepage — only listed as an offering
  • Named medical director / clinical leadership not disclosed
  • Refund and cancellation policy not detailed publicly
  • Corporate address and arbitration venue not disclosed
Ryze Rx

Graded #376 · C

Strengths

  • Compounded semaglutide and tirzepatide both $199/mo, with $499/$799 three-month bundles
  • Physician consultation, ongoing clinical support and discreet shipping included with each prescription
  • Broad catalog beyond GLP-1: TRT plus peptides (BPC-157, sermorelin, NAD+, retatrutide and more)
  • Free shipping, 24hr prescription turnaround, FSA/HSA eligible; care advertised in all 50 states

Where it loses points

  • Terms, Privacy Policy and HIPAA notice are dead links - no legal entity, refund policy or governing law disclosed
  • Pharmacy partners not named - only 'US-licensed compounding pharmacies'
  • Homepage advertises GLP-1s 'from $149/mo' but the catalog lists $199/mo
  • On-site '4.9/5, 2,400+ reviews' is self-reported, not an independently verified rating

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard